Artículos por temáticas

The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease.

Oñate M, Catenaccio A, Salvadores N, Saquel C, Martinez A, Moreno-Gonzalez I, Gamez N, Soto P, Soto C, Hetz C, Court FA.

Cell Death Differ. 2020 Apr;27(4):1169-1185. doi: 10.1038/s41418-019-0408-4. Epub 2019 Oct 7. Erratum in: Cell Death Differ. 2020 Feb 5;:.

Does restless legs syndrome impact cognitive function via sleep quality in adults with Parkinson's disease?

Cederberg KL, Brinkley EB, Belotserkovkaya N, Memon RA, Motl RW, Amara AW.

Int J Neurosci. 2020 Apr;130(4):322-329. doi: 10.1080/00207454.2019.1681423. Epub 2019 Oct 25.

Suicidal risk and demoralization in Parkinson disease.

Elfil M, Ahmed N, Alapati A, Bahekar R, Kandil M, Kim C, Schaefer S, Tinaz S, Patel AS, de Figueiredo JM, Louis ED, Koo BB.

J Neurol. 2020 Apr;267(4):966-974. doi: 10.1007/s00415-019-09632-2. Epub 2019 Dec 4.

Modulation of Nigrofugal and Pallidofugal Pathways in Deep Brain Stimulation for Parkinson Disease.

Avecillas-Chasin JM, Honey CR.

Neurosurgery. 2020 Apr 1;86(4):E387-E397. doi: 10.1093/neuros/nyz544.

2-(5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-N-(2-hydroxyethyl)-2-oxoacetamide (CDMPO) has anti-inflammatory properties in microglial cells and prevents neuronal and behavioral deficits in MPTP mouse model of Parkinson's disease.

Kim B, Park JY, Cho DY, Ko HM, Yoon SH, Choi DK.

Neuropharmacology. 2020 Apr;166:107928. doi: 10.1016/j.neuropharm.2019.107928. Epub 2019 Dec 27.

Should respiratory muscle training be part of the treatment of Parkinson's disease? A systematic review of randomized controlled trials.

Rodríguez MÁ, Crespo I, Del Valle M, Olmedillas H.

Clin Rehabil. 2020 Apr;34(4):429-437. doi: 10.1177/0269215519896054. Epub 2019 Dec 26.

Guideline for Botulinum Toxin Injections in the Effective Treatment of Fibular Spasticity.

Choi YJ, Cho TH, Won SY, Yang HM.

Clin Anat. 2020 Apr;33(3):365-369. doi: 10.1002/ca.23487. Epub 2019 Oct 18.

Adverse Event Profiles of High Dose Botulinum Toxin Injections for Spasticity.

Kirshblum S, Solinsky R, Jasey N, Hampton S, Didesch M, Seidel B, Botticello A.

PM R. 2020 Apr;12(4):349-355. doi: 10.1002/pmrj.12240. Epub 2019 Oct 1.

Intrathecal baclofen therapy for treatment of spasticity in infants and small children under 6 years of age.

Hagemann C, Schmitt I, Lischetzki G, Kunkel P.

Childs Nerv Syst. 2020 Apr;36(4):767-773. doi: 10.1007/s00381-019-04341-7. Epub 2019 Aug 9.

Test-retest reliability of the Dyskinesia Impairment Scale: measuring dystonia and choreoathetosis in dyskinetic cerebral palsy.

Vanmechelen I, Dan B, Feys H, Monbaliu E.

Dev Med Child Neurol. 2020 Apr;62(4):489-493. doi: 10.1111/dmcn.14424. Epub 2019 Dec 13.

Hemodynamic responses are abnormal in isolated cervical dystonia.

Berman BD, Groth CL, Shelton E, Sillau SH, Sutton B, Legget KT, Tregellas JR.

J Neurosci Res. 2020 Apr;98(4):692-703. doi: 10.1002/jnr.24547. Epub 2019 Nov 6.

A Systematic Review of Neuropsychiatric Symptoms and Functional Capacity in Huntington's Disease.

Sellers J, Ridner SH, Claassen DO.

J Neuropsychiatry Clin Neurosci. 2020 Spring;32(2):109-124. doi: 10.1176/appi.neuropsych.18120319. Epub 2019 Aug 30.

Cortical Network Dynamics Is Altered in Mouse Models of Huntington's Disease.

Donzis EJ, Estrada-Sánchez AM, Indersmitten T, Oikonomou K, Tran CH, Wang C, Latifi S, Golshani P, Cepeda C, Levine MS.

Cereb Cortex. 2020 Apr 14;30(4):2372-2388. doi: 10.1093/cercor/bhz245.

Late-onset Huntington's disease with 40-42 CAG expansion.

Capiluppi E, Romano L, Rebora P, Nanetti L, Castaldo A, Gellera C, Mariotti C, Macerollo A, Cislaghi MG.

Neurol Sci. 2020 Apr;41(4):869-876. doi: 10.1007/s10072-019-04177-8. Epub 2019 Dec 9.

Could metformin be therapeutically useful in Huntington's disease?

Tang BL.

Rev Neurosci. 2020 Apr 28;31(3):297-317. doi: 10.1515/revneuro-2019-0072.